Gossamer Bio (GOSS) Projected to Post Quarterly Earnings on Thursday

Gossamer Bio (NASDAQ:GOSS) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $7.5260 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 4:00 PM ET.

Gossamer Bio Price Performance

GOSS stock opened at $0.51 on Wednesday. Gossamer Bio has a 1-year low of $0.33 and a 1-year high of $3.87. The firm has a fifty day moving average price of $2.02 and a two-hundred day moving average price of $2.56. The firm has a market cap of $117.37 million, a price-to-earnings ratio of -0.73 and a beta of 2.08.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently made changes to their positions in GOSS. Bank of America Corp DE boosted its position in shares of Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock worth $77,000 after buying an additional 43,866 shares during the period. Invesco Ltd. bought a new stake in Gossamer Bio during the 1st quarter valued at $48,000. Cubist Systematic Strategies LLC acquired a new position in Gossamer Bio during the 1st quarter worth $213,000. Goldman Sachs Group Inc. grew its stake in shares of Gossamer Bio by 720.2% in the first quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock worth $1,034,000 after purchasing an additional 825,047 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Gossamer Bio by 5,250.1% in the first quarter. Jane Street Group LLC now owns 683,423 shares of the company’s stock worth $752,000 after purchasing an additional 670,649 shares in the last quarter. Institutional investors own 81.23% of the company’s stock.

Wall Street Analysts Forecast Growth

GOSS has been the subject of a number of recent research reports. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Barclays downgraded Gossamer Bio from an “overweight” rating to an “underweight” rating in a research note on Tuesday, February 24th. Oppenheimer dropped their price target on Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a research report on Thursday, March 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Finally, HC Wainwright reduced their price objective on Gossamer Bio from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.43.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.